Best GLP-1 Provider for People With IBS (2026): 6 Programs Compared

By the Weight Loss Provider Guide Research Team Last verified: August 11, 2026

Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers. We may earn a commission if you use some of the links on this page. The program we ranked first is not a commission-paying link on this page.

---

If you have IBS and you want to try a GLP-1, here's the short version.

The best GLP-1 provider for people with IBS is Form Health, because it's the only program we found that publicly includes monthly clinician visits, monthly registered-dietitian visits, and coordination with your own doctor. Self-pay care costs $299 a month, before medication and labs.

That's the answer for most people. It is not the answer for everyone — and price is not the main reason why.

Here's what almost nobody tells you: your IBS type changes the answer. And there is a pattern in Zepbound's FDA label that looks like it flips the usual advice about staying low. It doesn't prove that. It gives you a much better question to ask your prescriber.

We'll get to that in a minute. First, the quick decision.

One thing to be clear about up front: not one of these six companies publicly proves it specializes in IBS. We looked hard. So we didn't rank them on IBS expertise. We ranked them on what actually happens after your gut reacts — what clinical access they publish, whether the dose can be adjusted, whether a registered dietitian is included, and whether anyone will talk to the doctor who already knows your gut.

Jump to the full comparison ↓

---

Form Health is the best-supported option for most people with diagnosed, stable IBS, because its published program includes recurring clinician visits, registered-dietitian visits, secure messaging, and coordination with a patient's primary care doctor. Ro is the strongest path for FDA-approved medication and insurance help. Ivim Health publishes the most frequent licensed-provider access on a cash-pay plan, Sesame Care has the lowest standalone care fee, Embody has the lowest advertised compounded starting price, and MEDVi is another compounded option with a published 72-hour cancellation rule. No provider reviewed publicly documents IBS specialization.

We want to be honest about why we landed on Form Health, because it's not the answer an affiliate site is supposed to give.

Form Health is not a commission-paying link on this page. We're an independent comparison resource for GLP-1 telehealth providers, and we do earn money when readers sign up with some of the companies below. Form isn't one of them.

We put it first anyway, because when we lined up all six programs against the same list of features, Form was the only one that publicly documented all three of the things an IBS patient actually needs:

1. A clinician you see on video, on a schedule
2. A registered dietitian you see on video, on a schedule
3. A plan to review records and coordinate with your regular doctor

Everyone else was missing at least one. Usually the dietitian.

Why there's no single winner for everyone with IBS

Six things change the right answer:

• Is your IBS steady right now, or is it changing?
• Which pattern do you have — constipation (IBS-C), diarrhea (IBS-D), or both (IBS-M)?
• Do you need real food help, or just a prescription?
• Do you want an FDA-approved medication, or is compounded fine?
• Are you using insurance, or paying cash?
• What can you actually afford every month for a year?

Change any one of those and a different program wins. That's why the table above has six rows instead of one.

Who should close this page right now

If your gut symptoms are new, if they've changed from your normal pattern, if you're bleeding, vomiting repeatedly, losing weight without trying, or you're in the middle of a bad flare — a comparison page is the wrong next step.

Go see whoever manages your gut. Come back after.

We're not going to put a sign-up button in front of that. We mean it.

---

IBS is not listed as a contraindication in the current FDA prescribing information for Wegovy or Zepbound. Both current labels say the medication is not recommended in people with severe gastroparesis, a stomach-emptying disorder that is different from IBS. A prescribing clinician still has to decide whether your symptoms and medical history make treatment reasonable.

Short answer: IBS alone is not an FDA-listed reason you cannot take Wegovy or Zepbound.

We read the current FDA labels for Wegovy (semaglutide) and Zepbound (tirzepatide) ourselves — the actual prescribing information, not a summary. IBS does not appear in the contraindications section of either one. It is not named as a warning either.

But there is a gut restriction on both labels.

The label line that might actually apply to you

The current labels now land in the same place. An older Zepbound label used broader wording about severe gastrointestinal disease. The February 2026 label does not. So the old “Wegovy is narrow, Zepbound is broad” comparison is no longer current.

What this means for you, practically: a stable IBS diagnosis is not the same thing as severe gastroparesis. But if your symptoms are severe, new, or changing — especially early fullness, food sitting for hours, repeated vomiting, or upper-belly swelling — you need a clinician to sort out what is happening before you choose a drug or provider.

“Gastroparesis” means your stomach empties too slowly. It's a stomach problem. IBS mainly involves the intestines. They can feel similar — bloating, fullness, nausea — which is exactly why people mix them up. More on telling them apart further down.

You weren't named as an exclusion. You also weren't counted.

Here's something we found in our own research on GLP-1 trial rules, and it cuts both ways.

We went through the written eligibility rules for 17 pivotal weight-loss trials behind commonly used GLP-1 and GLP-1/GIP medications. The rules often screened for recent weight change, recent weight-loss drugs, pancreatitis, bariatric surgery, mental-health history, thyroid-cancer risk, cancer, kidney or liver problems, recent heart events, high blood pressure, eye disease, and slow stomach emptying.

IBS was not a named exclusion in the trial documents we reviewed.

That is a protocol audit, not proof that people with IBS enrolled. SURMOUNT-1, the main Zepbound trial, excluded people with a known clinically significant gastric-emptying abnormality and people using medications that directly affect gastrointestinal motility. STEP 1, the main Wegovy trial, did not name IBS in its published exclusion list.

So what does that mean? People with IBS may have been in these trials. They were not separated into an IBS subgroup, and no IBS-specific outcomes were reported.

IBS was not named as the reason to keep you out. Nobody counted you separately either.

One number shows how big the generalizability gap can be. In a US population study, 23.5% of adults who met FDA label criteria for tirzepatide reported using a medication that may slow gastrointestinal motility. When researchers added that trial-style criterion, the share meeting at least one tirzepatide exclusion rose from 33.1% to 43.7%.

That does not answer what happens in IBS. It proves why a prescriber needs your full medication list instead of treating an obesity-trial average as your personal forecast.

---

GLP-1 medications can cause both diarrhea and constipation. In Wegovy's adult injection trials for weight management, 30% of patients reported diarrhea and 24% reported constipation, versus 16% and 11% on placebo. About 73% reported some gastrointestinal reaction compared with 47% on placebo, and 4.3% stopped treatment because of one.

This is the single most useful fact on this page, and most articles get it backwards.

Everyone says GLP-1s cause constipation. That's true. What they leave out is that Wegovy caused diarrhea a little more often than constipation in its adult injection trials.

Here are the real numbers, straight from the current labels.

Wegovy injection (semaglutide 2.4 mg), adults, weight management

Source: Wegovy prescribing information, Table 3, revised 02/2026. These numbers are for the approved 2.4 mg injection trials, not every semaglutide product or compounded version.

Look at diarrhea and constipation. 30% and 24%. Almost the same.

This treatment can pull the gut in both directions. In these Wegovy injection trials, roughly a third reported looser stools and roughly a quarter reported constipation. That's not a contradiction — different bodies react differently.

So the real question isn't “will this upset my gut.” The honest answer is that it may, especially while the dose is rising. The real question is which direction, how severe, and can your care team respond. That's a question about your subtype, which is why this page is organized the way it is.

The rest of the picture, plainly

• About 73% of Wegovy injection patients reported some gut reaction. So did 47% of people on placebo — worth remembering. Some of this is just having a gut.
• Severe gut reactions: 4.1% on Wegovy injection vs 0.9% on placebo.
• 4.3% of Wegovy injection patients stopped because of a gut reaction, vs 0.7% on placebo.
• On Zepbound, 56% reported a gut reaction at every maintenance-dose level vs 30% on placebo. Between 1.9% and 4.3% stopped because of one, depending on dose.
• Both labels say most nausea, vomiting, and diarrhea happened while the dose was going up, and decreased over time.

For nausea, vomiting, and diarrhea, the rough part often clusters in the climb. That does not mean every gut problem fades, and it does not tell you what will happen to your IBS.

---

No conclusion like that can be drawn from the label. Zepbound's current FDA table reports constipation in 17% of the 5 mg group, 14% of the 10 mg group, and 11% of the 15 mg group, while diarrhea rises from 19% to 23%. Those are separate randomized maintenance-dose groups. The pattern is real, but it does not show that raising one person's dose will relieve constipation.

Okay. This is the thing we promised at the top.

If you have constipation-type IBS, you've probably heard: start low, move slowly, and don't raise the dose while your gut is struggling. That is sensible label-based dosing practice.

Then Zepbound's table shows a pattern that looks like the opposite.

Zepbound (tirzepatide), adults, weight management

Source: Zepbound prescribing information, Table 1, revised 02/2026.

Follow the constipation row. 17, then 14, then 11. It goes down across the three dose groups.

Now follow diarrhea. 19, 21, 23. Up.

They cross.

Every other gut reaction shown here either rises or stays close. Constipation is the one that runs the other way. We went through the current table column by column to check.

Now here's why you should not over-read it

We're going to talk you partly out of this, because you deserve the caveats in the same breath as the finding.

Those columns are separate groups of people, not a diary of one person moving from 5 to 10 to 15 mg. The higher-dose groups also moved through lower doses during escalation, and the table reports events over the study period rather than a clean “before and after” result for one patient.

Three facts stop this from becoming dose advice:

1. It is not a within-person comparison. A lower rate in the 15 mg group does not show that moving someone from 5 to 15 mg fixes constipation.
2. The table is not adjusted to prove cause. These are reported event percentages, not a statistical test showing a protective effect at higher doses.
3. Gut-related stopping rose with dose. Gastrointestinal reactions caused 1.9% of the 5 mg group, 3.3% of the 10 mg group, and 4.3% of the 15 mg group to stop treatment. “Higher is gentler” is not what the label says.

So what do you actually do with it? Not this: don't ask for a higher starting dose. Please don't.

Do this instead. Bring the pattern to your prescriber and say one sentence:

“I have constipation-type IBS. Zepbound's label shows constipation in 17%, 14%, and 11% across separate 5-, 10-, and 15-mg groups. I know that does not prove a higher dose would help me. How would you monitor me and decide whether to hold, slow, or stop escalation?”

That's it. That one sentence turns you from a patient hoping for the best into a patient with a specific question. Good clinicians love that question. It's the whole reason this section exists.

And this is exactly why the provider you pick matters. A program that can actually have that conversation — and can slow an increase when the plan and your symptoms call for it — is worth more to you than one that saves you $40 a month.

---

No GLP-1 medication is approved to treat IBS, and none should be used for that purpose. Research on GLP-1 signaling in IBS exists but is limited: an experimental analogue called ROSE-010 relieved acute IBS pain better than placebo in a 166-patient randomized trial, with the strongest signal in constipation-predominant and mixed IBS, and a 2026 report described two patients whose treatment-resistant IBS-D resolved while taking semaglutide.

Most people arrive here assuming “slows your gut down” is obviously bad news for IBS. The research is stranger than that.

A GLP-1 analogue was once studied specifically for IBS pain. It was called ROSE-010. In a randomized, placebo-controlled trial of 166 patients, given as a single injection for a pain attack, about twice as many people got meaningful pain relief as on placebo — 24% and 23% at the two doses versus 12% on placebo.

And when researchers went back through that same 166-patient dataset later, they found the pain-relief signal was strongest in IBS-C and IBS-M. The constipation and mixed groups. Not IBS-D.

Separately, semaglutide has been reported to stop severe diarrhea in two people with IBS-D. The published report described two women — one 67, one 23 — with long-standing, treatment-resistant IBS-D whose diarrhea resolved while taking semaglutide, along with major weight loss.

A different compassionate-use case series followed 30 people with severe diarrhea from mixed causes, not 9 people with IBS. Their median daily bowel movements dropped from 8 to 2. That is interesting evidence about diarrhea. It is not an IBS trial, and it should not be presented as one.

And now the other side, with equal weight. Case reports have linked semaglutide with pseudo-obstruction and bowel blockage. The current Wegovy label also lists voluntary postmarketing reports of ileus, intestinal obstruction, and severe constipation including fecal impaction; Zepbound lists ileus. Voluntary reports cannot tell us how often these events happen or prove the drug caused every report.

A 2025 systematic review included five publications on GLP-1-related approaches in IBS. But two publications analyzed the same 166-patient ROSE-010 trial, so “five independent trials” would be wrong. The review found a pain-relief signal and also more nausea, vomiting, and headache.

What we make of all this

Three separate lines of evidence, all pointing at the same organ, and none strong enough to settle what will happen to you.

The mechanism is not a promise. What matters is which gut it lands in.

That's the whole argument for sorting this decision by subtype and care structure instead of by a drug-brand slogan.

To be completely clear: two IBS-D cases are not proof. A 2009 trial of an unapproved drug given for an acute pain attack is not the same thing as taking Wegovy every week. No GLP-1 is approved for IBS, and nobody should take one hoping to treat their IBS. We're telling you this so you stop assuming the worst — not so you start assuming the best.

Why your gastroenterologist's guidelines don't mention any of this

Here's the gap that explains why every answer you've gotten so far has felt like a shrug.

The American Gastroenterological Association publishes treatment guidelines many gut clinicians use. Its 2022 IBS-C guideline and IBS-D guideline name specific drugs:

• For IBS-C: linaclotide (recommended); plus tenapanor, plecanatide, tegaserod, lubiprostone, and PEG laxatives
• For IBS-D: rifaximin, eluxadoline, alosetron, loperamide, tricyclic antidepressants, antispasmodics — and they suggest against SSRIs

GLP-1s appear in neither list.

And as we covered, IBS appears nowhere on the Wegovy or Zepbound labels.

So you're standing between two sets of official documents that don't reference each other. The obesity side doesn't name your condition. The gut side doesn't name your drug. That's not a scandal. It means nobody's official paperwork gives you an IBS-specific treatment answer. Which is why the person you pick to manage this matters so much more than usual.

---

Because no telehealth provider publishes IBS-specific outcome data, the useful criteria are structural: whether a clinician can hold or slow a dose increase, what licensed-provider access is actually documented, whether a registered dietitian is included, whether you can identify the exact medication and dispensing pharmacy, and whether the team will coordinate with an existing doctor.

Nobody can tell you which company is gentlest on IBS. So stop asking that. Here are the five things you can check before you pay anyone.

1. Can they hold your dose?

This is the big one, and it's not a marketing feature — it's in the label.

Wegovy's own prescribing information says that if a patient doesn't tolerate a dose during escalation, delaying the increase for four weeks may be considered. The FDA-approved instructions build in a pause.

So a program that marches you up a fixed calendar regardless of how you feel is genuinely worse for you than one that adjusts. Ask directly: "Can the prescriber delay a dose increase if my gut is struggling, and how do I request that?"

"Titration" just means raising the dose in steps. Never change a dose yourself.

2. Who actually answers when your gut reacts?

Watch this one carefully, because the wording is slippery.

"24/7 support" very often means 24/7 customer service — billing, shipping, order questions. It does not always mean a licensed prescriber is reading your message about symptoms.

One question settles it: "If I message about a symptom, is a licensed prescriber reading it, or is it support staff?"

For you specifically, this is the difference between getting a real answer and getting "that's normal, keep going."

3. Is a registered dietitian actually included?

These four things are not the same, and companies use them interchangeably:

• A registered dietitian — credentialed, can build a real plan around your triggers
• A health coach — supportive, not a nutrition clinician
• A nutrition guide — a PDF
• An automated meal plan — software

For someone with IBS, this matters more than for the average GLP-1 patient. Your food already needs managing. Now you're adding a drug that changes how much you eat and how fast it moves. If you're considering something like a low-FODMAP approach — a temporary elimination diet used for IBS — you want an actual dietitian, not an app.

Ask: "Is a registered dietitian included, is that guaranteed or does it depend on my insurance, and do they have IBS experience?"

4. Can you identify the exact medication and pharmacy?

With an FDA-approved brand — Wegovy, Zepbound, Ozempic, Mounjaro, or Foundayo — the product has one FDA label that lists its active and inactive ingredients, strengths, dosing instructions, and studied adverse reactions. The label numbers on this page describe the specific approved products and trial formulations named here. They do not predict your personal result.

With a compounded medication, there is no single FDA label that covers every version. The dispensing pharmacy, concentration, inactive ingredients, vial size, and dosing units can differ. Ask for all five before it ships.

“Compounded” means a pharmacy or outsourcing facility prepares the drug under compounding rules instead of a manufacturer selling that exact product under an FDA approval. Compounded medications are not FDA-approved and do not go through FDA premarket review for safety, effectiveness, or quality.

The FDA says compounded GLP-1 drugs should be used only when a patient's medical need cannot be met by an FDA-approved drug. For someone with a diagnosed gut condition, that is a real trade-off — not a reason to pretend the option does not exist, but a reason to know exactly what you're choosing.

5. Will they talk to the doctor who already knows your gut?

If you have IBS, someone has probably already tested you, ruled things out, and helped you find what works. That history is valuable.

Most telehealth programs in our table do not publicly document outside-doctor coordination. Form Health does.

---

Across six programs, only Form Health publicly documents recurring clinician visits, recurring registered-dietitian visits, and primary-care coordination together. Standalone care fees run from $59 per month with an annual Sesame subscription to $299 per month with Form Health. Embody advertises the lowest bundled compounded starting price at $79 per month, while most FDA-approved medication routes bill medication separately.

This is the table we built the page around. Same questions asked of every program, using public program, pricing, FAQ, safety, and terms pages checked August 11, 2026.

Read that last row again. Every single one is a no. Any page that tells you a specific company specializes in IBS is telling you something it can't back up.

Provider-stated vs. independently verified

What “not documented” means — and doesn't

If a cell says “not documented,” it means we could not find it on the company's public pages as of August 11, 2026. It does not mean the company doesn't do it. They might. They just don't say so publicly, which means you can't rely on it before you pay.

That distinction matters, so we're not going to blur it. If a provider can show us documentation, we'll update the table and log the change.

A note on the numbers you won't see here: we deliberately did not give these programs scores out of 100. A weighted score would look precise and wouldn't be. What features a company publishes is checkable. How good their care is isn't something we can measure from the outside, and pretending otherwise would be the exact thing we're criticizing.

---

Form Health's published program includes a monthly clinician video visit, a monthly registered-dietitian video visit, team messaging, medical-record review, and coordination with a patient's primary care doctor, using FDA-approved medications. Self-pay care is $299 per month, with medication and labs billed separately. Form generally expects patients to have seen a primary care provider within the past 12 months.

Here's what Form publicly includes:

• Monthly video visit with a clinician
• Monthly video visit with a registered dietitian
• Messaging with the care team
• Review of your medical records
• Coordination with your primary care doctor
• Side-effect and medication management
• FDA-approved medications, not a compounded package

Now line that up against the five things we said matter for IBS. Form is the only program on our list that publicly documents both the dietitian and outside-doctor coordination. No other program in our six-provider table documents that pair.

Why that combination fits IBS specifically: food is already half of your management. A drug that changes how much you eat and how fast it moves needs someone watching the food side, not just the dose. And the doctor who already tested you and figured out your triggers has information no intake form will ever capture.

We're not claiming Form prevents flares. Nobody can claim that. We're saying its structure is built for the situation you're actually in.

The honest problem with Form Health

Here's the part where we lose some of you, and we'd rather do it now than after you've paid.

Form Health has more onboarding steps, and it is not cheap. Care is $299 a month before medication and labs, and Form generally expects you to have seen your own doctor within the last 12 months. If you want the lowest monthly number, Form is the wrong pick — Sesame Care is cheaper at $59 a month with an annual subscription, and Ivim publishes unlimited video visits.

But that doctor requirement is the reason Form can do the thing nobody else in our table documents. Because Form requires that connection and a medical-record release, it can coordinate with whoever manages your IBS. Form treats your history as a medical record to read, not just a line on the signup form.

If you've spent years getting your IBS half-figured-out, that's not a hoop. That's the whole point.

Choose Form Health if

• Your IBS is diagnosed and steady
• You want real food help from a registered dietitian
• You want FDA-approved medication
• You already have a regular doctor
• You'd rather pay more for support than less for a prescription

Choose something else if

• $299 a month before medication isn't realistic
• You want a compounded, lower-cost option
• You don't have a recent doctor relationship
• You want more than one clinician visit a month

→ If that sounds like your situation: See Form Health's program details and eligibility requirements

---

Ro is the strongest option for people who want FDA-approved medication, insurance assistance, or help with prior authorization. Its current page lists Wegovy tablets, Wegovy pens, Foundayo tablets, and Zepbound KwikPen for cash pay, plus an insurance check for Ozempic, Wegovy, and Zepbound autoinjector pens. Membership is $39 for the first month, then $149 per month, or as low as $74 per month with an annual plan paid upfront. Medication is billed separately.

For a lot of readers, Ro is going to be the practical answer — and there's a specific reason it fits people with IBS better than it fits the average shopper.

The medical event rates on this page came from FDA labels. The 30% diarrhea figure. The 24% constipation figure. The 17-14-11 cross-arm pattern. Those numbers describe the approved Wegovy injection and Zepbound products and trial groups named in the tables.

If you take the approved product named in a label, you and your prescriber have a standardized product, a Medication Guide, listed ingredients, and product-specific dosing instructions. The trial rate still does not predict what will happen to you, and one approved product's rates should not be copied onto another.

If you take a compounded version, there is no single FDA label that covers every pharmacy's formulation and concentration. That's not a scare tactic — plenty of people choose compounded care. But for someone with a diagnosed gut condition, knowing the exact product, concentration, pharmacy, and dosing units is worth something real.

What Ro brings

• FDA-approved medication currently listed: Wegovy tablets, Wegovy pens, Foundayo tablets, and Zepbound KwikPen
• A free insurance check for select Ozempic, Wegovy, and Zepbound pen routes
• An insurance concierge and prior-authorization help
• On-demand provider support, 1:1 messaging, check-ins, dose adjustments, and side-effect management

Why the insurance piece matters: IBS itself is not a magic coverage ticket. The value is that someone else handles the plan's paperwork while your prescriber handles the medical decision. You can check the insurance route before paying for a full program.

Ro's pricing, straight

Get started for $39, then as low as $74 a month with an annual plan paid upfront. Six-month and three-month prepaid plans are also listed, and month-to-month is $149. Medication costs are separate from the membership — that catches people off guard, so we're saying it twice.

Choose Ro if

• You want FDA-approved, brand-name medication
• You have insurance and want help using it
• You want product-specific labels and Medication Guides
• You want dose support without a $299 self-pay care fee

→ If insurance or FDA-approved medication is your priority: Check Ro's current coverage, medication, and membership options

The insurance check is free. That's the lowest-commitment way to find out whether the covered route is real for your plan.

---

Ivim Health publicly describes unlimited video visits with licensed providers, text or call access advertised 24/7, weekly dose adjustments, personalized titration, and health coaching. Membership is free for the first month and $75 per month afterward. Its lowest published medication pricing uses prepaid compounded programs, including semaglutide at $499 for four months and tirzepatide at $900 for four months.

If the thing keeping you up at night is “what if my gut reacts and nobody answers,” Ivim addresses access more directly than most programs on this list.

What Ivim publicly includes:

• Unlimited video visits with licensed providers
• Text or call access advertised 24/7
• Weekly dose adjustments and a personalized titration schedule
• Medication refills and adjustments
• One-to-one health coaching

For an IBS-D reader especially — where vomiting or diarrhea can turn into dehydration — frequent provider access can be genuinely valuable. It gives you more than one scheduled monthly window to ask what to do next.

What Ivim does not publicly prove: registered-dietitian inclusion, IBS specialization, gastroenterologist access, a same-day visit guarantee, or a guaranteed clinician response time for a flare. We looked. Marked as not documented, not as absent.

Ivim's pricing, with the catch stated plainly

• First month of membership: free
• After that: $75/month
• Compounded semaglutide packages: $499 for four months, $600 for six months
• Compounded tirzepatide packages: $900 for four months, $1,100 for six months

The catch: the published lower medication prices require several months of commitment. Ivim's membership agreement says accepted fees are nonrefundable, members are responsible for the full contract duration, and mid-term cancellation is not allowed. Read the agreement before you pay. This is not “cancel anytime.”

If prepaying months up front makes you nervous — and for a first GLP-1 with an existing gut condition, that's a fair thing to be nervous about — Sesame's annual care subscription or Ro's month-to-month membership gives you a different commitment structure. Compare the total, not just the first screen.

The advertised Ivim packages here are compounded. Compounded medications are not FDA-approved and do not go through FDA premarket review for safety, effectiveness, or quality. A licensed clinician decides whether treatment is appropriate.

Ivim's 2026 FDA warning letter

On February 20, 2026, FDA sent Ivim a warning letter about website material the agency reviewed in December 2025. FDA alleged that product images and labeling made it appear Ivim was the compounder or manufacturer when it was not, and that the presentation made certain products misbranded. A warning letter is not a court judgment, and it describes the site FDA reviewed at that time. It is still a regulatory fact a reasonable buyer should know.

→ If frequent provider access is what you need most: Review Ivim's current prices and read the membership agreement before checkout

---

Sesame Care's GLP-1 program starts at $59 per month with an annual subscription and includes a provider you choose, ongoing video care, unlimited messaging, labs, and side-effect tools. Medication costs are separate. Sesame lists FDA-approved medication options when clinically appropriate.

If your IBS is already diagnosed, already steady, and you mostly need a competent clinician without a premium care fee, Sesame is the value pick.

What the $59 covers: a dedicated provider you choose, video visits, unlimited messaging, labs, ongoing care, and treatment adjustments.

What it doesn't: medication. And a registered dietitian isn't part of the public program description.

The feature that's underrated for people like you

Sesame lets you pick your clinician. You can look at profiles before booking, and its public page describes ongoing care with a dedicated provider.

That's not nothing when you have a gut condition. You get to look for someone whose background suggests they'll take “I have IBS-M and I'm scared of this” seriously, instead of being assigned whoever is next in the queue.

Just don't over-read a profile. A bio doesn't prove IBS expertise, and we did not enroll to test whether every visit stays with the same person. But choosing and having a named provider beats not knowing who will see you next.

What Sesame publicly proves about continuity

Sesame says you work one-to-one with a dedicated provider and can continue through video visits and messaging. That is provider-stated continuity, not an independent service test. It is still more concrete than a vague “support included” promise.

Be clear on the price: $59 a month is the care fee with an annual subscription. It is not your total cost. Medication is separate, and you should read the current subscription terms before committing for a year.

→ If your IBS is steady and you want to choose your own clinician: Browse Sesame's current GLP-1 care and provider options

---

Embody has the lowest advertised compounded starting price in this comparison: GLP-1 injections from $79 per month and GLP-1/GIP injections from $129 per month, with no separate membership fee shown. MEDVi starts at $179 for injections and $249 for tablets, and it publishes a 72-hour cancellation deadline. Both rely mainly on compounded medications that are not FDA-approved.

Money is a real constraint. If $299 or even $149 a month isn't happening, this is your lane — and we'd rather help you do it carefully than pretend the option doesn't exist.

Embody

What it publicly offers:

• Compounded GLP-1 injections starting at $79/month
• Compounded GLP-1/GIP injections starting at $129/month
• No separate membership or hidden-fee claim on the public page
• Unlimited appointments
• Care-team messaging as often as needed
• Direct-to-door shipping

The catch: “starting at” is not a full checkout total. Confirm the plan length, amount due today, renewal date, pharmacy, concentration, inactive ingredients, vial size, and dosing units before you pay. We did not find public proof of a registered dietitian or IBS-specific care.

Embody's public safety page states that its compounded medications have not been evaluated or approved by FDA for safety, effectiveness, or quality.

MEDVi

What it publicly offers:

• Injections starting at $179/month
• Tablets starting at $249/month
• One-to-one physician guidance
• Patient support described as available day and night
• Care coaching

The compounded disclosure, before the button, not after it:

MEDVi's main shipped options are compounded medications. Compounded medications are not FDA-approved. FDA does not review them for safety, effectiveness, or quality before sale the way it reviews an approved drug. MEDVi's current page says it does not make the compounded medication itself and names partner pharmacies.

For someone with a diagnosed gut condition, ask MEDVi for the exact dispensing pharmacy, concentration, ingredients, and dosing units before shipment. “Compounded semaglutide” is not enough detail.

The cancellation term: you must cancel at least 72 hours before the next billing date. MEDVi says people medically disqualified may receive a full refund; ordinary monthly cancellation does not automatically refund the current month. Put the deadline in your calendar the day you sign up.

MEDVi's 2026 FDA warning letter

On February 20, 2026, FDA sent MEDVi a warning letter about website material the agency reviewed in December 2025. FDA alleged that the site's product presentation made MEDVi look like the compounder and that “same active ingredient” claims could imply FDA approval or evaluation that compounded products do not have. A warning letter is not a court judgment, and MEDVi's current page now says it does not produce the compounded medications. We found no public FDA closeout letter, so the warning belongs in the decision.

The FDA rule that should shape this choice

FDA says compounded GLP-1 drugs should be used only when a patient's medical need cannot be met by an FDA-approved drug. That does not erase the cost problem. It means you should check the approved route and coverage first, then choose compounded care with your eyes open if the approved route does not meet your need.

→ If cost is your deciding factor and you understand the compounded trade-off: compare Embody's current starting prices with MEDVi's current prices and 72-hour cancellation policy

A licensed clinician decides whether treatment is appropriate. If you'd rather have an FDA-approved medication, go back to the Ro section — the free coverage check may make the approved route cheaper than the sticker price suggests.

---

These providers were not excluded for being poor programs. They did not rank for this specific query because the public materials we checked did not document a stronger combination of clinician continuity, registered-dietitian access, dose-adjustment support, and outside-care coordination for a patient with existing IBS.

We looked at more programs than the six above. Here's honestly why they're not in the table.

Eden. A strong broad offer. But one correction worth making, because we've seen it repeated: Eden's current public pricing shows a separate membership — $39 for the first month, then $99 per month — on top of medication. Anyone telling you Eden has no membership fee is working from old information. No IBS-specific care advantage was publicly documented.

Yucca Health. We did not find public IBS outcome data or a stronger documented combination of dietitian access, dose-adjustment support, and outside-doctor coordination than the programs ranked above.

SHED and other oral or needle-free programs. Useful if injections are your barrier. But route of administration does not prove a medication is gentler on IBS, and we won't imply it does.

TrimRx. We found no public IBS outcome data or documented IBS-care structure strong enough to displace the six-program comparison above. We are not using complaint volume as a medical-quality score.

Hims and Hers. They may be practical routes for specific approved medications. They did not show a stronger IBS-specific care structure in the public materials used for this comparison.

No button in this section. That's the point — it shows you we were choosing, not listing everyone who might pay us.

---

IBS subtype changes which provider features matter most, but it does not establish which GLP-1 medication is better. Constipation-predominant IBS raises the value of dietitian access and a written constipation plan, diarrhea-predominant IBS raises the value of fast clinical access and hydration guidance, and mixed IBS makes continuity more valuable because the pattern can shift.

This is where the label data and the provider data finally meet.

The IBS subtype register

Note on the postmarketing rows: those are voluntary reports. They tell you what has been reported, not how often it happens, and they cannot be used to compare one drug's risk against another's.

If you have IBS-C

Your risk runs toward being backed up. So: get a constipation plan in writing before your first dose, not after you're stuck. Weight the dietitian heavily. Confirm you can reach a prescriber before a dose increase. Ask about other medications you take that also cause constipation.

Route: Form Health first for the registered dietitian and doctor coordination. Ro second if FDA-approved medication and insurance help matter more.

If you have IBS-D

Your risk runs toward fluid loss. Both labels warn about kidney injury tied to dehydration from vomiting or diarrhea. So: frequent clinical access matters. Ask what symptoms should trigger same-day contact and what you should do before your next dose if you cannot eat or drink normally.

Route: Ivim for unlimited video visits and 24/7 text/call access as advertised. Form if you want the full structure and registered-dietitian care.

If you have IBS-M

You need continuity most, because your pattern can flip. A clinician who knows your normal pattern can tell that something changed faster than someone starting from zero.

Route: Form Health for scheduled same-team visits and record coordination. Sesame second for its dedicated-provider model.

If you don't know your subtype

Don't guess, and don't let a quiz diagnose it. Go to a clinician-led program with a live visit, or ask your own doctor. Price should not be the first filter until you know what pattern you are dealing with.

One more thing, and it's important: if you are planning a strict elimination diet such as low-FODMAP, ask your clinician or registered dietitian whether to change one thing at a time. Starting a new medication and a major diet change together can make it harder to tell what caused a symptom.

---

Timing is the most useful clue, not a diagnosis. Gastrointestinal side effects from GLP-1 medications often cluster after starting treatment or increasing a dose, and both the Wegovy and Zepbound labels say most nausea, vomiting, and diarrhea occurred during dose escalation and decreased over time. An IBS flare may follow a person's established triggers. New or severe symptoms need clinical review.

You will ask this question. Probably in week two or three. Here's how to think about it.

Three tests:

1. Timing. Did it start within a few days of your first dose or a dose increase? That points toward the medication. Both labels put most nausea, vomiting, and diarrhea in the escalation window.
2. Trigger. Did you eat something, travel, sleep badly, get stressed, or hit a point in your cycle that normally sets you off? That points toward a flare.
3. Familiarity. Have you felt exactly this before? IBS is miserable but often familiar. Genuinely new sensations deserve a phone call.

The highest-value thing you can do: keep a two-line log every day for the first eight weeks. Date, medication and dose, what you ate, what your gut did, 1–10. Nothing fancy. When you message your clinician, that log turns “my stomach hurts” into something a prescriber can actually act on.

Symptoms that need same-day advice or urgent care

Calm, short list. Not a complete emergency guide.

• No bowel movement or no gas, plus a swollen belly, vomiting, and severe pain. Current labels include postmarketing reports of ileus or intestinal obstruction. This pattern needs urgent in-person care.
• You cannot keep fluids down, are barely urinating, feel faint, or show other dehydration signs. Vomiting and diarrhea can lead to acute kidney injury from volume loss.
• Severe belly pain that will not let up or spreads to your back, with or without vomiting. The labels tell patients to stop the medicine and contact a clinician right away for suspected pancreatitis.
• Blood in your stool, black stools, rectal bleeding, or losing weight you did not intend to lose. These can point to something other than IBS and need evaluation.

For anything on that list, don't message a weight-loss app and wait. Get same-day medical advice or urgent in-person care. Call 911 for collapse, trouble breathing, severe chest pressure, or another life-threatening emergency.

For the fuller symptom ladder, see our guide to GLP-1 side effects and when to worry. For exactly how to word a message, see when to message your GLP-1 provider about side effects.

The message that gets a real answer

Fill this in and send it. It forces a clinical reply instead of “that's normal.”

“I have diagnosed [IBS-C / IBS-D / IBS-M]. My usual pattern is [describe it]. I started [medication] on [date] and my last dose change was [date]. Since [date] I've had [symptoms]. I [can / cannot] keep fluids down. I am urinating [normally / less than usual]. This feels [the same as / different from] my usual IBS. My next dose is due [date]. Please tell me what to do before I take it.”

→ Copy that message now. Don't wait until you feel too sick to build it.

IBS + GLP-1 appointment sheet

Use your browser's Print command and choose “Save as PDF,” or copy this block into your notes.

• My IBS type: IBS-C / IBS-D / IBS-M / not sure
• My normal bowel pattern:
• My usual triggers:
• My current GLP-1 and form:
• My current dose:
• Date of first dose:
• Date of last dose increase:
• New symptom and start date:
• Same as my usual IBS, or different:
• Can I keep fluids down? yes / no
• Am I urinating normally? yes / no
• My next dose is due:
• Other medicines that affect my gut:
• My question: Should we hold, slow, change, or continue the current plan?

Bring the Zepbound cross-arm numbers only as a question, not as a reason to change your own dose: constipation 17% / 14% / 11%; diarrhea 19% / 21% / 23% across separate dose groups.

---

Advertised medication prices rarely represent total cost. Standalone care fees in this comparison run from $59 per month with a Sesame annual subscription to $299 per month with Form Health. Embody advertises a bundled compounded starting price from $79 per month. Medication, commitment length, dose, and renewal rules can change what you actually spend.

Nobody shows you this next table, and it's the one that changes decisions.

The cash-outlay math the ads do not put together

• Form Health: 12 months of self-pay care is $3,588, before medication and labs.
• Sesame: 12 months of care at $59 is $708, before medication.
• Ro: the lowest ongoing membership is $74 a month but is prepaid as $888 after the $39 first month. That is a $927 cash outlay before medication when you start the intro month and then enter the 12-month prepaid plan; it covers 13 months of membership in total.
• Ivim: a four-month semaglutide package is $499 due under the published offer, plus $75 monthly after the free first month. If the membership bills for the remaining three months, that is $724 over four months before any add-ons. The same math is $1,125 for the $900 four-month tirzepatide package. Confirm the exact billing schedule in writing before paying.
• MEDVi and Embody: “starting at” prices are not enough to calculate a reliable 12-month total. Dose, plan, renewal, and checkout terms have to be known first.

The three questions that reveal your real cost

1. What do I pay today?
2. What do I pay in month two? This is where introductory pricing bites.
3. What's my total for twelve months, including medication, care, labs, shipping, and required prepayment?

Why the cheapest program can end up costing more

If your program can't help when your gut reacts, you may end up:

• Paying your own doctor for another visit
• Paying separately for a registered dietitian
• Losing prepaid months because you had to stop
• Starting over somewhere else

We're not saying that will happen. We're saying it's the cost nobody puts in the comparison. Both current labels show that gut reactions are common, so support is not a made-up concern. A lower-fee program that cannot adjust your plan may cost you more than a higher-fee program that can.

---

The most useful pre-purchase questions are operational rather than promotional: who responds to symptom messages, whether a dose increase can be delayed, whether nutrition support is included and guaranteed, whether the team coordinates with outside providers, and what the total cost and cancellation terms are.

Copy these. Send them to support chat before you enter a card. How they answer tells you as much as what they answer.

Access

1. If I message about a symptom, is a licensed prescriber reading it, or support staff?
2. Can I see the same or a matched clinician each time?
3. How quickly does a clinician respond to gut symptoms? Is that a guarantee?
4. Is there clinical coverage on weekends?

IBS and dosing

5. Does your intake ask whether I have IBS-C, IBS-D, or IBS-M?
6. Can the prescriber delay a dose increase if my gut is struggling? How do I request that?
7. Will you coordinate with my primary care doctor or gastroenterologist?

Nutrition

8. Is a registered dietitian included? Is that guaranteed, or does it depend on my insurance?
9. Does the dietitian have IBS experience?

Money and medication

10. Is the medication FDA-approved or compounded? If compounded, what are the pharmacy name, concentration, inactive ingredients, vial size, and dosing units?
11. What do I pay today, and what do I pay in month two? Are labs and shipping included?
12. What's the cancellation deadline, and what happens to my money if the clinician says I'm not a candidate?

If a company won't answer #1, #6, or #12 clearly in writing, that's your answer. Also search the provider and dispensing pharmacy in the FDA warning-letter database before you pay.

---

Online provider comparison is not the right next step when digestive symptoms are new, changing rapidly, severe, or hard to separate from another condition. Repeated vomiting, inability to maintain fluids, rectal bleeding, black stools, or unintended weight loss require individual medical evaluation.

There's no button in this section. On purpose.

Start with your own doctor, a gastroenterologist, or in-person urgent care if:

• Your symptoms are new and haven't been evaluated
• Your symptoms have changed from your normal pattern
• You have bleeding, black stools, or unintended weight loss — these can point to something other than IBS
• You're in the middle of a bad flare right now, so you couldn't tell what a drug was doing anyway
• You have signs that could suggest slow stomach emptying — feeling full very early, staying full for hours, repeated vomiting, upper-belly pain, or swelling
• You take long-term medication that changes gut motility and need a full medication review
• You've had a bowel obstruction, ileus, or major abdominal surgery and the telehealth program cannot review those records

That last group matters. Both current labels say Wegovy and Zepbound are not recommended in people with severe gastroparesis. Neither label says IBS itself is a contraindication. The hard part is telling stable IBS from a different motility problem, and that call belongs to a clinician with your history in front of them.

We intentionally do not place provider links in this section. The right next step here is a medical evaluation, not choosing an offer.

If that's you, our GLP-1 contraindications guide will help you separate a true FDA contraindication from a warning that needs discussion. Come back when you've had that conversation.

---

This page uses current FDA prescribing information and gastroenterology guidance for medical facts, provider-owned pages for price and feature claims, public terms for commitment rules, and peer-reviewed publications for the IBS evidence. Provider claims were normalized into the same fields. Anything we could not confirm was labeled instead of guessed.

Who wrote this: the Weight Loss Provider Guide Research Team. We're an independent comparison resource for GLP-1 telehealth providers. No clinician reviewed this page, and we're not going to put a fake reviewer name on it to look more official.

Where the medical facts came from

• Wegovy prescribing information, revised 02/2026 — contraindications, severe-gut warning, dose-delay instruction, adverse-reaction table, and postmarketing section
• Zepbound prescribing information, revised 02/2026 — same sections, including the current Table 1
• American Gastroenterological Association 2022 guidelines for IBS-C and IBS-D
• NIDDK information on IBS, including symptoms, diagnosis, subtypes, and diet
• The 2009 ROSE-010 randomized trial and the 2022 subtype reanalysis of the same patient dataset
• The 2025 systematic review of GLP-1-related IBS publications
• The 2026 two-patient IBS-D report and the separate 30-patient mixed-cause severe-diarrhea case series
• Bessette and Anderson's JAMA Internal Medicine analysis of trial generalizability
• Our own protocol register covering 17 pivotal weight-loss trials

Where the commercial facts came from

Each provider's own public pricing, program, FAQ, safety, and terms pages, checked August 11, 2026:

• Form Health FAQs
• Ro pricing and medication options
• Ivim pricing and membership agreement
• Sesame weight-loss program
• MEDVi program page and cancellation policy
• Embody program page
• Eden's public pricing page

We also checked the FDA's current page on unapproved compounded GLP-1 drugs, plus the February 20, 2026 warning letters for Ivim and MEDVi.

What we actually verified

We checked provider pricing, published clinician access, messaging, dietitian access, medication type, and available cancellation or commitment terms on the dates listed. We read the current FDA labels ourselves and went through the adverse-reaction tables column by column.

That is how we found two things other pages keep missing:

1. The current Zepbound label no longer uses the old broad “severe gastrointestinal disease” wording.
2. The 17% / 14% / 11% constipation pattern is real, but it is a cross-arm pattern and not evidence that increasing one person's dose will help constipation.

What we did not do

We did not enroll in these programs. We did not receive medication. We did not time their clinical response. We did not test their cancellation processes. We did not inspect a shipment or verify a patient's dispensing pharmacy. We found no public evidence that any of the six specializes in IBS or has IBS-specific outcome data.

Where a table says “not documented,” we could not confirm it publicly. That is not the same as “they don't offer it.”

Material corrections in this version

Affiliate disclosure

We may earn a commission if you use some of the provider links on this page. The program we ranked first is not a commission-paying link on this page. We built the comparison around the care structure and then checked which programs had commercial relationships — not the other way around.

Found an outdated price or policy? Send us the current primary source and we'll update this page and log the change.

---

Is IBS a contraindication for Wegovy or Zepbound?

No. IBS is not listed in the contraindications section of either current FDA label. Both labels say the medication is not recommended in people with severe gastroparesis. That is a warning and precaution, not an IBS contraindication. Your prescriber decides whether your symptoms and history make treatment appropriate.

Can a GLP-1 make IBS worse?

It can cause or worsen symptoms that overlap with IBS. In Wegovy's adult injection trials, diarrhea was reported by 30% of patients versus 16% on placebo, and constipation by 24% versus 11%. Your IBS subtype does not reliably predict which direction you will go.

Can a GLP-1 help IBS-D?

No GLP-1 is approved to treat IBS, and none should be used for that purpose. A 2026 report described two people with treatment-resistant IBS-D whose diarrhea resolved while taking semaglutide. A separate 30-person case series found fewer daily bowel movements in severe diarrhea from mixed causes. Interesting is not the same as proven.

Will a GLP-1 make my IBS-C worse?

It can. Constipation is one of the most common reactions in both labels' weight-management trials. Get a constipation plan from your clinician before your first dose, not after you're stuck, and put registered-dietitian access high on your provider list.

Which GLP-1 is easiest on the stomach?

Nobody knows for people with IBS. Wegovy and Zepbound were tested in separate trials with different designs and patients. FDA labels warn that adverse-event rates from separate trials cannot be compared as if they were a head-to-head test. There is no head-to-head IBS trial.

Is oral or needle-free semaglutide easier on IBS?

Don't assume so. Wegovy now has both an approved injection and an approved tablet, and its current label says the types and frequency of common reactions with the tablet were similar to the injection table. Route can matter for convenience or needle fear. It does not prove gut gentleness.

Does starting at a lower dose prevent an IBS flare?

It can help a clinician manage tolerability, but it does not guarantee a flare-free start. Wegovy's label allows considering a four-week delay in an injection dose increase when a dose is not tolerated. The Zepbound 17% / 14% / 11% constipation pattern comes from separate dose groups and should not be used to change your own dose.

Can a GLP-1 cause gastroparesis?

Both labels warn about severe gastrointestinal reactions and say the medication is not recommended in severe gastroparesis. If you have early fullness, food sitting for hours, repeated vomiting, or upper-belly swelling, get medical evaluation instead of trying to diagnose yourself from an article.

How do I tell an IBS flare from a side effect?

Timing, trigger, and familiarity. Side effects often cluster after starting or increasing a dose. Flares may follow your known triggers. Genuinely new or severe symptoms deserve a call. Your prescriber can make a better decision when you bring a dose-and-symptom log.

Should I tell my GLP-1 provider I have IBS?

Yes. Always. Every time. Leaving it out doesn't get you approved faster — it just means the person adjusting your dose is working without the most relevant fact about your gut.

Can I take my IBS medication with a GLP-1?

It depends on the medication. Wegovy and Zepbound delay gastric emptying and may affect absorption of oral drugs. Bring a full medication list to the prescriber and ask your pharmacist about timing and monitoring. Do not stop an IBS medicine on your own.

Do I need a provider with a dietitian?

It helps when food triggers, fiber changes, reduced intake, or low-FODMAP planning are in play. Of the six programs compared, Form Health is the only one whose public program clearly includes recurring registered-dietitian visits.

Are compounded GLP-1 medications FDA-approved?

No. Compounded medications are not FDA-approved and do not go through FDA premarket review for safety, effectiveness, or quality. FDA says compounded GLP-1 drugs should be used only when a patient's medical need cannot be met by an approved drug. Ask for the exact pharmacy, concentration, ingredients, and dosing units.

Did FDA send warning letters to Ivim and MEDVi?

Yes. FDA sent both companies warning letters dated February 20, 2026 about website presentation and labeling or approval implications. Warning letters state the agency's allegations and requested corrections; they are not court judgments. The letters are still part of the regulatory record and belong in a buyer's decision.

Is $299 a month worth it for Form Health?

It depends on what you need. If you want a recurring registered dietitian, coordination with your own doctor, and FDA-approved medication, it is the only package in our six-program table that publicly documents all three. If you just want the lowest monthly number, it is not — Sesame's care fee is $59 with an annual subscription, and Embody advertises compounded injections from $79.

Is Sesame's $59 the whole cost?

No. That's the care fee with an annual subscription. Medication is separate.

Does Ro's membership include the medication?

No. Ro's membership and medication are billed separately. Membership is $39 the first month, then $149 monthly or as low as $74 monthly with an annual prepaid plan.

What if no provider can confirm IBS experience?

None of the six publicly proves it, which is why we ranked on care structure instead. Pick a program that documents the support you need, or start with the doctor already managing your IBS. What you shouldn't do is pick from the lowest introductory price and hope.

---

Get my IBS-aware GLP-1 action plan

You'll get a care path matched to your subtype, your symptom stability, your medication preference, your coverage, and your budget — plus the questions to bring to your appointment.

The quiz doesn't diagnose IBS and doesn't decide whether you can take a medication. It sorts what you already know into a decision.

---

Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers. This page is for general information and is not medical advice. Only a licensed clinician can decide whether a GLP-1 medication is appropriate for you.

Last verified: August 11, 2026

---